JAMA Psychiatry最新文献

{"title":"Do Likes Reinforce Depression?","authors":"Quentin J M Huys, Amy Orben","doi":"10.1001/jamapsychiatry.2026.1373","DOIUrl":"10.1001/jamapsychiatry.2026.1373","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"898-899"},"PeriodicalIF":18.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide in Schizophrenia-A Top Clinical Trial.","authors":"Dost Öngür","doi":"10.1001/jamapsychiatry.2026.2043","DOIUrl":"10.1001/jamapsychiatry.2026.2043","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"900"},"PeriodicalIF":18.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Failure to Update ClinicalTrials.gov Record for a Clinical Trial.","authors":"Dost Ongur","doi":"10.1001/jamapsychiatry.2026.2544","DOIUrl":"10.1001/jamapsychiatry.2026.2544","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"901"},"PeriodicalIF":18.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal Interoception and Relapse in Anorexia Nervosa.","authors":"Charles Verdonk, Keller Mink, Emily Choquette, Scott E Moseman, Ahmad Mayeli, Jennifer L Stewart, Martin P Paulus, Ryan Smith, Sahib S Khalsa","doi":"10.1001/jamapsychiatry.2026.1301","DOIUrl":"10.1001/jamapsychiatry.2026.1301","url":null,"abstract":"<p><strong>Importance: </strong>Anorexia nervosa (AN) is a deadly psychiatric disorder with relapse rates approaching 50% after weight restoration. Disrupted gastrointestinal interoception may underlie persistent symptoms and relapse vulnerability.</p><p><strong>Objective: </strong>To examine behavioral, computational, neural, and physiological markers of gastrointestinal interoception in weight-restored individuals with AN and test their association with relapse.</p><p><strong>Design, setting, and participants: </strong>This crossover trial was a single-blind, within-participant, randomized (block-order) trial conducted at the Laureate Institute for Brain Research between August 2021 and February 2025. Participants were females with weight-restored restrictive AN and age- and sex-matched healthy comparators (HCs). All participants ingested a vibrating capsule that delivered counterbalanced blocks of normal- and enhanced-intensity gut stimulation. Behavioral detection performance, electroencephalography, peripheral physiology, and computational modeling were used to assess interoception.</p><p><strong>Main outcomes and measures: </strong>Experimental-session measures included interoceptive accuracy, prior beliefs, interoceptive precision, learning rates, gastric-evoked potentials (GEPs), and hunger. Main clinical outcomes at 6 months included relapse status and symptom severity.</p><p><strong>Results: </strong>The cohort included 62 female participants with weight-restored restrictive AN (mean [SD] age, 18.9 [4.5] years) and 57 age- and sex-matched healthy comparators (HCs; mean [SD] age, 20.7 [5.3] years). Six-month follow-up data were collected for 54 participants with AN. Compared with HCs, participants with AN showed lower perceptual accuracy (Cohen d = -0.98; 95% CI, -1.51 to -0.44; P = .001) and higher miss rates (Cohen d = 1.02; 95% CI, 0.55 to 1.48; P < .001). Computational modeling revealed in the AN group stronger prior expectations that capsule vibrations would not be present (Cohen d = -0.31; 95% CI, -0.67 to 0.05; P = .05), greater shifts in interoceptive precision between blocks (Cohen d = 0.38; 95% CI, 0.02 to 0.75; P = .01), and learning asymmetries (vibration: Cohen d = -0.40; 95% CI, -0.77 to -0.04; P = .007; no-vibration: Cohen d = 0.35; 95% CI, -0.02 to 0.71; P = .01). GEP amplitudes did not differ by group but were correlated with accuracy and learning in AN. Capsule stimulation induced greater hunger increases in AN (interaction: η2p = 0.04, P = .04; AN: Cohen d = 0.94; 95% CI, 0.57 to 1.30; HCs: Cohen d = 0.40; 95% CI, 0.03 to 0.77). At follow-up, relapse was predicted by initial priors (odds ratio [OR], 3.82; 95% CI, 1.02 to 15.91; P = .05), response bias (OR, 5.37; 95% CI, 1.15 to 32.04; P = .04), and stomach unpleasantness (OR, 5.73; 95% CI, 1.38 to 33.5; P = .03), while eating disorder symptom severity was predicted by miss rate (β = 1.05; R2 = 0.08; P = .05), difference in interoceptive precision (β = 5.84; R2 = 0.16; ","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"902-911"},"PeriodicalIF":18.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13276667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapting Family-Based Psychosis Care to the Digital Home","authors":"Apurva Parikh, Geoffrey Russell, John M. Kane, David J. Miklowitz","doi":"10.1001/jamapsychiatry.2026.2570","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2570","url":null,"abstract":"This Viewpoint describes how family-based care for psychosis should adapt to a home that now extends into online spaces without treating digital life primarily as a source of risk.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"10 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness","authors":"Roger S. McIntyre, Yanli Zhang-James, Angela T. H. Kwan","doi":"10.1001/jamapsychiatry.2026.2574","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2574","url":null,"abstract":"Importance Bipolar disorder, major depressive disorder, and schizophrenia are associated with substantial excess mortality, principally from cardiovascular disease. Identifying strategies to reduce this burden is a critical psychiatric priority. Objective To evaluate associations between initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors and all-cause mortality and major adverse cardiovascular events (MACEs) among adults with and without serious mental illness (SMI). Design, Setting, and Participants This was a retrospective target trial emulation within the TriNetX Analytics Network, a multinational federated electronic health record network. Adults initiating GLP-1 RAs or SGLT2 inhibitors were included using a new-user, active-comparator design with propensity score matching and separate psychiatric and nonpsychiatric cohorts. The study included all available data in the TriNetX network through the most recent database refresh. Data were queried and analyzed in March 2026, with prespecified follow-up intervals of 1, 4, and 10 years. Additional subgroup analyses were conducted following peer review in May 2026. Exposure First-recorded GLP-1 RA vs SGLT2 inhibitor prescription. Main Outcomes and Measures The primary outcome was 4-year all-cause mortality; the key secondary outcome, 1-year mortality. Additional outcomes included 3- and 5-point MACEs and individual cardiovascular end points. Sensitivity analyses included diabetes stratification, exclusion of baseline heart failure and chronic kidney disease, and censoring at crossover. Exploratory analyses examined SMI subgroups, agent-specific effects, and combination therapy. Results For the primary 4-year analysis, 1 528 230 adults were propensity score matched (764 115 pairs; 195 184 pairs with serious mental illness [SMI] and 568 931 pairs without SMI). The mean [SD] age in the GLP-1RA and SGLT2 inhibitor groups was 60.5 [12.0] and 60.2 [13.3] years, respectively, in the SMI cohort and 60.9 [12.2] and 60.6 [13.0] years, respectively, in the non-SMI cohort; 112 911 [57.8%], 113 488 [58.1%], 251 679 [44.2%], and 260 480 [45.8%] were female, respectively. Among participants with SMI, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (9585 of 195 184 [4.91%] vs 12 584 of 195 184 [6.45%]; hazard ratio [HR], 0.76; 95% CI, 0.74-0.78; absolute risk difference [ARD], −1.54 percentage points; 95% CI, −1.68 to −1.39; <jats:italic toggle=\"yes\">P</jats:italic> < .001). Among participants with SMI and type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower risks of 3-point MACE (HR, 0.77; 95% CI, 0.76-0.79), 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. In a separately matched 1-year SMI cohort, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (2898 of 198 065; 1.4","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"24 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential for Genomics to Help Guide Preventive Strategies in Psychiatry","authors":"Katherine L. Musliner, Eva C. Schulte, Gerome Breen, Giuseppe Fanelli, Andreas J. Forstner, Philip R. Jansen, Kimberley M. Kendall, Jurjen Luykx, Vincent Millischer, Sergi Papiol, Evangelos Vassos, Boris Chaumette, Wouter J. Peyrot","doi":"10.1001/jamapsychiatry.2026.2583","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2583","url":null,"abstract":"Importance Psychiatric disorders are a major source of disability and premature mortality worldwide. Advances in genomics have clarified parts of their genetic architecture, prompting questions about whether genomic information can inform preventive strategies for psychiatric disorders in clinical practice. This Special Communication describes potential benefits and harms of using genomic information, particularly polygenic scores (PGSs) and rare variants, to guide prevention in psychiatry. Observations Broad application of genomic testing in universal or selective primary prevention is not currently supported by evidence of net clinical benefit, given modest absolute risk differences, limited individual-level predictive performance, and the potential for psychological harm. The possible value of genomic testing increases for indicated primary prevention, as prior probability rises and diagnostic uncertainty becomes clinically relevant. The most compelling opportunity lies in early care after individuals enter the psychiatric treatment system but before diagnostic trajectories fully crystallize. In this zone of diagnostic uncertainty, testing for rare, high-impact variants can shorten diagnostic delays, inform prognosis, and guide monitoring and treatment, provided that results are communicated appropriately. PGSs may contribute to risk stratification when applied in high-risk clinical populations and integrated with nongenetic factors. In secondary and tertiary prevention, pharmacogenomics provides actionable benefits for medication choice and safety, and rare variant testing has clear value in selected instances. Beyond psychiatric outcomes, genomic testing could potentially help address the profound mortality gap in severe mental illness by identifying elevated risk for somatic comorbidities, thus supporting more proactive, integrated care. Conclusions and Relevance Currently, genomic testing in psychiatry should not be used for population-wide screening but may have value as a targeted clinical resource whose utility depends on timing, context, and purpose. When applied judiciously and embedded within comprehensive, ethically grounded care pathways, genomic testing holds promise as one component of a more precise, preventive, and patient-centered psychiatry.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"6 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148815511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neural Markers of Reward Valuation and Impulsive Decision-Making in Mania Risk","authors":"Robert Raeder, Manan Arora, Neil Jones, Henry W. Chase, Michele Bertocci, Luke T. Roberts, Genna Bebko, Haris A. Aslam, Simona Graur, Megan Taylor, Megan Atkinson, Osasumwen Benjamin, Yiming Wang, Richelle Stiffler, Mary L. Phillips","doi":"10.1001/jamapsychiatry.2026.2510","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2510","url":null,"abstract":"Importance Mania or hypomania, the pathognomonic feature of bipolar disorder (BD), is associated with reward hypersensitivity and impulsive decision-making, but the neural mechanisms underlying these distinct behavioral facets remain unclear. Reward expectancy (RE)–associated activation in the left ventrolateral prefrontal cortex (L-vlPFC) and pre–supplementary motor area (pre-SMA) is elevated in individuals at risk of mania or hypomania, but it is unknown whether elevated activation in these regions and associations with risk-related behavioral facets reflect convergent or dissociable pathways to mania or hypomania risk or whether depression severity impacts these associations. Objective To test whether RE-associated L-vlPFC and pre-SMA activation exhibit distinct associations with delay discounting behavior—indexing reward valuation (lower discounting) vs impulsive decision-making (higher discounting)—and whether these associations are moderated by depression severity. Design, Setting, and Participants In this cross-sectional study, 2 independent samples of adults aged approximately 18 to 30 years at varying risk of mania or hypomania (142 in the discovery set and 86 in the replication set) completed a functional magnetic resonance imaging reward task and a delay discounting assessment. Major exclusion criteria included current or lifetime BD, primary psychotic disorders, neurological disorders, recent substance use disorders, systemic medical illnesses, and magnetic resonance imaging contraindications. The study took place from 2019 to 2026 at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania. Exposure RE-associated L-vlPFC and pre-SMA activation. Main Outcomes and Measures Main outcomes were mania or hypomania risk per Mood Spectrum Self-Report–Lifetime mania score and delay discounting behavior per 27-Item Monetary Choice Questionnaire rate. Associations were tested using regression models, including moderation by depression severity. Results Across 228 individuals (discovery: mean [SD] age, 23.79 [3.32] years; 96 [67.6%] female; replication: mean [SD] age, 26.09 [3.15] years; 64 [74.4%] female), L-vlPFC and pre-SMA activation were both positively associated with mania or hypomania risk in the discovery sample (l-vlPFC: β, 0.544; 95% CI, 0.440 to 0.649; <jats:italic toggle=\"yes\">z</jats:italic> , 10.24; <jats:italic toggle=\"yes\">P</jats:italic> < .001 and pre-SMA: β, 0.496; 95% CI, 0.341 to 0.650; <jats:italic toggle=\"yes\">z</jats:italic> , 6.30; <jats:italic toggle=\"yes\">P</jats:italic> < .001) and replication sample (l-vlPFC: β, 0.503; 95% CI, 0.241 to 0.765; <jats:italic toggle=\"yes\">z</jats:italic> , 3.77; <jats:italic toggle=\"yes\">P</jats:italic> < .001 and pre-SMA: β, 0.684; 95% CI, 0.410 to 0.957; <jats:italic toggle=\"yes\">z</jats:italic> , 4.90; <jats:italic toggle=\"yes\">P</jats:italic> < .001). In the discovery sample, these regions showed dissociable delay discountin","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"27 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the Prevalence and Severity of Alcohol and Cannabis Use Disorders Among US Adults","authors":"Beth Han, Wilson M. Compton, Jennifer A. Hobin, Nora D. Volkow","doi":"10.1001/jamapsychiatry.2026.2497","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2497","url":null,"abstract":"Importance The number of US adults with alcohol use disorder (AUD) has declined, whereas the number with cannabis use disorder (CUD) has increased. Little is known about how changes in the prevalence and severity of AUD and CUD vary by age and sex. Objective To investigate trends in AUD and CUD prevalence and severity by age and sex. Design, Setting, and Participants This cross-sectional study examined data from adult participants in the 2021 to 2024 National Surveys on Drug Use and Health. This study was started and completed in March 2026. Exposure Alcohol and cannabis use. Main Outcomes and Measures Past-year prevalence and severity of AUD and CUD using <jats:italic toggle=\"yes\">DSM-5</jats:italic> criteria. Results From 2021 through 2024 among 186 823 participants (51.3% female; 4.9% aged 18-20 years; 24.1% aged 21-34 years; 24.7% aged 35-49 years), past-year CUD prevalence increased among males (from 7.3% [95% CI, 6.6%-8.1%] to 9.3% [95% CI, 8.6%-10.1%]; <jats:italic toggle=\"yes\">P</jats:italic> < .001) and females (from 4.5% [95% CI, 4.1%-5.0%] to 5.6% [95% CI, 5.2%-6.1%]; <jats:italic toggle=\"yes\">P</jats:italic> = .01). Moderate-to-severe CUD prevalence among males increased from 3.1% (95% CI, 2.8%-3.6%) to 4.1% (95% CI, 3.7%-4.5%) ( <jats:italic toggle=\"yes\">P</jats:italic> < .001), especially among males aged 35 to 49 years (from 2.7% [95% CI, 2.0%-3.6%] to 3.9% [95% CI, 3.2%-4.8%]; <jats:italic toggle=\"yes\">P</jats:italic> = .01) and males aged 50 years or older (from 0.6% [95% CI, 0.3%-1.0%] to 1.2% [95% CI, 0.8%-1.7%]; <jats:italic toggle=\"yes\">P</jats:italic> = .02). Among females, moderate-to-severe CUD prevalence increased from 1.7% (95% CI, 1.5%-2.0%) to 2.5% (95% CI, 2.3%-2.8%) ( <jats:italic toggle=\"yes\">P</jats:italic> < .001), specifically for females aged 21 to 34 years (from 4.2% [95% CI, 3.5%-5.1%] to 5.6% [95% CI, 4.8%-6.5%]; <jats:italic toggle=\"yes\">P</jats:italic> = .04), 35 to 49 years (from 1.2% [95% CI, 0.8%-1.8%] to 2.0% [95% CI, 1.6%-2.5%]; <jats:italic toggle=\"yes\">P</jats:italic> = .01), and 50 years or older (from 0.1% [95% CI, 0.04%-0.3%] to 0.7% [95% CI, 0.5%-1.0%]; <jats:italic toggle=\"yes\">P</jats:italic> < .001). Among females with CUD, moderate-to-severe CUD prevalence increased from 37.0% (95% CI, 32.5%-41.8%) to 45.0% (95% CI, 41.1%-49.0%) ( <jats:italic toggle=\"yes\">P</jats:italic> = .03). However, moderate-to-severe AUD prevalence remained stable among males overall (except for declines among males aged 21-34 years) and was stable among females overall and within all subgroups. Most males and females aged 18 to 20 years and males aged 21 to 34 years with CUD had moderate-to-severe CUD (eg, 51.0%-61.0% in 2024), with consistent patterns from 2022 through 2024. Conclusions and Relevance This cross-sectional study found divergent age- and sex-specific patterns from 2021 through 2024, with moderate-to-severe CUD prevalence increasing and moderate-to-severe AUD p","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"193 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Interacting With Artificial Intelligence Cause Delusions?","authors":"Philip R. Corlett","doi":"10.1001/jamapsychiatry.2026.2500","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2026.2500","url":null,"abstract":"This article implores clinicians to consider whether artificial intelligence models may induce delusionlike beliefs—and how to help overcome this phenomenon.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"1 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}